TITLE:
Anemia in Chronic Hemodialysis at the Fousseyni Daou Hospital in Kaye, Mali: Management Challenges
AUTHORS:
Aboubacar Sidiki Fofana, Magara Samaké, Seydou Sy, Moctar Coulibaly, Youssouf Singadou Ousmane Djiguiba, Samba Konaré, Niagalé Diakité, Pinda Tounkara, Modi Sidibé, Djeneba Maiga, Sah Dit Baba Coulibaly, Nouhoum Coulibaly, Hamadoun Yattara, Saharé Fongoro
KEYWORDS:
Anaemia, Chronic Haemodialysis, Kayes Hospital, Mali
JOURNAL NAME:
Open Journal of Nephrology,
Vol.15 No.4,
December
23,
2025
ABSTRACT: Introduction: Anaemia is one of the most common complications of Chronic Kidney Disease (CKD) and significantly impairs the quality of life of patients undergoing chronic haemodialysis. The aim of this study was to describe the clinical, therapeutic, and evolutionary aspects of anaemia in chronic haemodialysis patients at Fousseyni Daou Hospital in Kayes, Mali. Methodology: We conducted a prospective, descriptive cohort study lasting four months, from 1 June to 1 October 2025, at the haemodialysis centre of the Fousseyni Daou Hospital in Kayes. Patients who had been on chronic haemodialysis for at least three months and had a haemoglobin level below 11 g/dl on their blood count were included. Results: During the study period, 70 patients out of 117 participants were selected, including 39 women (55.7%) and 31 men (44.3%). The average age was 46.97 years ± 14.20. The average duration of haemodialysis was 21 months. The mean haemoglobin level was 7.91 g/dl ± 1.47. Twenty-seven patients (38.6%) had a haemoglobin level below 8 g/dl. The respective means for ferritin and saturation coefficient were 1044.60 ng/ml ± 477.98 and 31.10% ± 7.33%. Ferritin levels were below 500 ng/ml in 8 patients (11.4%), and the saturation coefficient was below 30% in 22 patients (31.4%). Blood transfusions were performed in 90% of patients. Intravenous iron supplementation was performed in 62 patients (88.6%). Erythropoietin (EPO) was administered occasionally in 44 patients (62.9%). Eleven patients (15.7%) received EPO at the optimal therapeutic dose (loading and maintenance dose) per week. Among the 11 patients who received optimal EPO treatment, 8 achieved a mean target haemoglobin level of 11 g/dl during the study period. Conclusion: Managing anaemia in haemodialysis patients in our context remains a real challenge. Optimising EPO treatment is still hampered by limiting factors, particularly economic ones. It must be integrated into a sound national policy for care provided by the competent health authorities.